Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Income from Continuing Operations of 49013000.0 for Q1 2026, down 20.14% on a YoY basis from 61370419.36 in Q1 2025, and up 83.98% sequentially from 305942000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Income from Continuing Operations data on file, last reported at 49013000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 20.14% year-over-year to 49013000.0; the trailing twelve-month figure through Mar 2026 stood at 431736000.0 (down 4.15% YoY), and the FY2025 full-year result was 423521000.0, down 5.56% from the prior year.
- Income from Continuing Operations grew to 49013000.0 in Q1 2026, from 305942000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 16524000.0 in Q2 2022 to a low of 307059000.0 in Q4 2024.
- A 5-year average of 62902647.06 and a median of 32563000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 40.27% in 2022 and tumbled 916.89% in 2024, its largest moves.
- Tracing EWTX's Income from Continuing Operations over 5 years: stood at 19847000.0 in 2022, then plunged by 52.14% to 30196000.0 in 2023, then plunged by 916.89% to 307059000.0 in 2024, then grew by 0.36% to 305942000.0 in 2025, then jumped by 83.98% to 49013000.0 in 2026.
- Business Quant data shows EWTX's Income from Continuing Operations at 49013000.0 in Q1 2026, 305942000.0 in Q4 2025, and 40666000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | -49.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.01 Mn |
| Dec 31, 2025 | -305.94 Mn |
| Sep 30, 2025 | -40.67 Mn |
| Jun 30, 2025 | -36.12 Mn |
| Mar 31, 2025 | -40.80 Mn |
| Dec 31, 2024 | -307.06 Mn |
| Sep 30, 2024 | -34.13 Mn |
| Jun 30, 2024 | -32.56 Mn |
| Mar 31, 2024 | -34.90 Mn |
| Dec 31, 2023 | -30.20 Mn |
| Sep 30, 2023 | -27.01 Mn |
| Jun 30, 2023 | -28.49 Mn |
| Mar 31, 2023 | -29.93 Mn |
| Dec 31, 2022 | -19.85 Mn |
| Sep 30, 2022 | -18.20 Mn |
| Jun 30, 2022 | -16.52 Mn |
| Mar 31, 2022 | -17.96 Mn |
| Dec 31, 2021 | -33.23 Mn |
| Sep 30, 2021 | -12.95 Mn |
| Jun 30, 2021 | -10.35 Mn |